Frank A. Post

Overview

Best Publications

• Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

  Paul E Sax;David Wohl;Michael T Yin;Frank Post

  754
  Citations

• Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

  Paul E. Sax;Kristine M. Erlandson;Jordan E. Lake;Grace A. McComsey

  729
  Citations

• Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy

  Margaret T. May;Mark Gompels;Valerie Delpech;Kholoud Porter

  714
  Citations

• Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study

  Margaret T May;Mark Gompels;Valerie Delpech;Kholoud Porter

  485
  Citations

• British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012

  Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  484
  Citations

• Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).

  Amanda Mocroft;Jens D Lundgren;Jens D Lundgren;Miriam Lewis Sabin;Antonella d'Arminio Monforte

  448
  Citations

• Mycobacterium tuberculosis Growth at the Cavity Surface: a Microenvironment with Failed Immunity

  Gilla Kaplan;Frank A. Post;Andre L. Moreira;Helen Wainwright

  447
  Citations

• Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

  Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  430
  Citations

• Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients

  Juliano Timm;Frank A. Post;Linda-Gail Bekker;Gabriele B. Walther

  321
  Citations

• Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.

  Clark D Russell;Cameron J Fairfield;Thomas M Drake;Lance Turtle

  310
  Citations

• Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

  Frank A Post;Graeme J Moyle;Hans Jürgen Stellbrink;Pere Domingo

  291
  Citations

• British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

  Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  280
  Citations

• Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study

  Paul E. Sax;Andrew Zolopa;Indira Brar;Richard Elion

  270
  Citations

• Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

  Charles R. Swanepoel;Mohamed G. Atta;Vivette D. D’Agati;Michelle M. Estrella

  262
  Citations

• Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

  Anton Pozniak;Jose R. Arribas;Joseph Gathe;Samir K. Gupta

  258
  Citations

• Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.

  Tanya Welz;Kate Childs;Fowzia Ibrahim;Mary Poulton

  250
  Citations

• British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011

  D Asboe;C Aitken;M Boffito;C Booth

  237
  Citations

• Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.

  Chloe I Bloom;Thomas M Drake;Annemarie B Docherty;Brian J Lipworth

  187
  Citations

• Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

  Samir K. Gupta;Frank A. Post;José R. Arribas;Joseph J. Eron

  185
  Citations

• Pulmonary tuberculosis in HIV infection: Radiographic appearance is related to CD4+ T-lymphocyte count

  Frank Post;R Wood;G P Pillay

  182
  Citations

• Spectrum of chronic kidney disease in HIV‐infected patients

  Lj J. Campbell;F. Ibrahim;M. Fisher;Sg G. Holt

  176
  Citations

• Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

  Nicholas I. Paton;Ruth L. Goodall;David T. Dunn;Samuel Franzen

  175
  Citations

• CD4 and total lymphocyte counts as predictors of HIV disease progression.

  Frank Post;R Wood;G Maartens

  134
  Citations

• HIV care and the incidence of acute renal failure.

  Jennifer Roe;Lucy J. Campbell;Fowzia Ibrahim;Bruce M. Hendry

  133
  Citations

• Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

  S Fidler;W Stöhr;M Pace;L Dorrell

  129
  Citations

• British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

  Duncan Churchill;Laura Waters;Nadia Ahmed;Brian Angus

  107
  Citations